How risk assessment can support proportionate extractables and leachables study design under the draft ICH Q3E framework without relying on one-size-fits-all testing.
The draft ICH Q3E framework does not imply that every product requires the same E&L study programme. The extent of analytical and toxicological work should be scientifically justified and proportionate to the risk.
What can increase the required study depth?
Higher patient exposure potential, greater product-component interaction, materials with less favorable or poorly characterized extractables profiles, severe manufacturing conditions and formulations with stronger leaching propensity can all support a broader study or stronger controls.
What can support a reduced or streamlined approach?
Relevant prior knowledge, low product-contact potential, effective barriers, well-characterized materials, favorable process conditions and robust existing data can support a more focused strategy when the justification is scientifically defensible.
Risk assessment does not equal automatic exemption
A risk tool can organize evidence and identify major drivers, but the final study strategy should be justified in the context of the product, materials, process, clinical use and applicable regulatory expectations.
Lifecycle management
Changes in suppliers, components, materials, formulation, manufacturing, sterilization, packaging or clinical use can alter the original risk profile and may trigger reassessment.
Documentation matters
The rationale for reduced, expanded or alternative testing should be transparent, traceable and proportionate to both the magnitude of risk and the uncertainty in the supporting evidence.
Frequently asked questions
Does every drug product need the same E&L study package?
No. ICH Q3E is risk-based and the study programme should be proportionate to the product and system.
Can prior knowledge reduce testing?
Yes, if the data are relevant, reliable and applicable to the intended use.
Can a risk assessment automatically exempt a product from E&L testing?
No. It supports scientific justification; the final decision depends on the complete evidence and regulatory context.
When should the E&L risk assessment be revisited?
When changes to materials, suppliers, process, formulation, packaging, sterilization or clinical use could alter the risk.
Why is uncertainty important?
Greater uncertainty can justify more conservative or more extensive study and control measures.
